reports
- Oliver Metzger
- Thomas Zlowodzki
- Oliver Metzger
- Thomas Zlowodzki
- Damien Choplain
- Martial Descoutures
- Damien Choplain
- Martial Descoutures
- Amira Manai
- Gautier Le Bihan
- Amira Manai
- Gautier Le Bihan
Abivax Presents First Quarter 2025 Financial Results
Abivax Presents First Quarter 2025 Financial Results Abivax Presents First Quarter 2025 Financial Results PARIS, France, June 2, 2025, 10:00 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today its key financial results for the quarter ended March 31, 2025. Abivax provided the following updates on its business...
- Antoine Lebourgeois
- Aurelien Deside
- Antoine Lebourgeois
Ekinops adds SSE capabilities with Olfeo buyout
Ekinops has signed an agreement to acquire Olfeo, a French cybersecurity software vendor focused on Security Service Edge (SSE) solutions. The deal adds EUR6.3m in ARR (>20% EBITDA margin) and is fully cash-funded. While the price remains undisclosed, Ekinops’ post-transaction net cash position
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trial...
Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis The Phase 3 ABTECT trials (Studies 105 and 106) evaluating obefazimod in patients with moderately to severely active ulcerative colitis successfully enrolled 1,275 participants, exceeding the target enrollment of 1,224 by 4%.Top-line results from the 8-week induction trials anticipated in Q3 2025, with 44-week mainten...
Abivax Announces Annual General Meeting Details as Company Advances To...
Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones Annual General Meeting scheduled for Friday, June 6, 2025, in Paris, FrancePhase 3 ABTECT induction trials remain on track: enrollment completion expected in Q2 2025, with top-line induction results expected in Q3 2025 PARIS, France – April 22, 2025 – 10:05 PM CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage ...
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directo...
Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chr...
- Julian Dobrovolschi
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
ALLIX WALLIX GROUP SA
DB1 DEUTSCHE BOERSE AG
AAL ANGLO AMERICAN PLC
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
MF WENDEL SE
LSEG LONDON STOCK EXCHANGE GROUP PLC
LEI LEIFHEIT AG
SZG SALZGITTER AG
GXI GERRESHEIMER AG
EKI EKINOPS SA
RF EURAZEO SA
ALCLS CELLECTIS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
A1XA4J CARBIOS SA
ERA ERAMET SA
POS PORR AG
ROS ROSENBAUER INTERNATIONAL AG
NDA AURUBIS AG
KRN KRONES AG
PAT PATRIZIA AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
TKO TIKEHAU CAPITAL SCA
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
ANTIN ANTIN INFRASTRUCTURE PARTNERS
ALLFG ALLFUNDS (UK) LTD
FLOW FLOW TRADERS LTD
SCHOTT PHARMA AG
CVC CVC CAPITAL PARTNERS PLC
HAVAS HAVAS N.V
- Julian Dobrovolschi
TKA THYSSENKRUPP AG
MT ARCELORMITTAL SA
BEKB BEKAERT SA
ALLIX WALLIX GROUP SA
DB1 DEUTSCHE BOERSE AG
AAL ANGLO AMERICAN PLC
APAML APERAM SA
OUT1V OUTOKUMPU OYJ
SSAB A SSAB AB CLASS A
MF WENDEL SE
LSEG LONDON STOCK EXCHANGE GROUP PLC
LEI LEIFHEIT AG
SZG SALZGITTER AG
GXI GERRESHEIMER AG
EKI EKINOPS SA
RF EURAZEO SA
ALCLS CELLECTIS SA
VOE VOESTALPINE AG
ACX ACERINOX SA
A1XA4J CARBIOS SA
ERA ERAMET SA
POS PORR AG
ROS ROSENBAUER INTERNATIONAL AG
NDA AURUBIS AG
KRN KRONES AG
PAT PATRIZIA AG
AMG AMG ADVANCED METALLURGICAL GROUP N.V.
RIO RIO TINTO PLC
TKO TIKEHAU CAPITAL SCA
BHP BHP GROUP LTD
AMAG AMAG AUSTRIA METALL AG
ANTIN ANTIN INFRASTRUCTURE PARTNERS
ALLFG ALLFUNDS (UK) LTD
FLOW FLOW TRADERS LTD
SCHOTT PHARMA AG
CVC CVC CAPITAL PARTNERS PLC
HAVAS HAVAS N.V
- Amira Manai
- Gautier Le Bihan
- Antoine Lebourgeois
Ekinops: still no breakout in Q1
Ekinops has reported Q1 2025 revenue of EUR28.5m, up 1% yoy, extending the run of quarterly prints within the EUR28–30m range, with no discernible inflection. Underlying dynamics remain uneven: North America declined 20% yoy, offset by a 21% rebound in EMEA; Access Solutions rose 11%, while Optical
- Amira Manai
- Gautier Le Bihan
EQS-News: Abivax publishes financial reports with the French and U.S....
EQS-News: ABIVAX / Key word(s): Annual Report Abivax publishes financial reports with the French and U.S. securities regulatory agencies 26.03.2025 / 22:05 CET/CEST The issuer is solely responsible for the content of this announcement. Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms t...
Abivax publishes financial reports with the French and U.S. securities...
Abivax publishes financial reports with the French and U.S. securities regulatory agencies Abivax publishes financial reports with the French and U.S. securities regulatory agencies PARIS, France – March 26, 2025 – 10:05 PM CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announces the filing of its Universal Registration Document (Document d’Enregistrement...
- Stephane Beyazian
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.